eXoZymes Partners With B2i Digital to Showcase Cell-Free Biomanufacturing Platform

eXoZymes Inc. has been named a B2i Digital Featured Company, bringing attention to its innovative cell-free biomanufacturing platform that represents a significant advancement in sustainable industrial biotechnology. The partnership will showcase eXoZymes' AI-guided enzyme technology to B2i Digital's sophisticated investor community, highlighting the platform's potential to address scale-up bottlenecks in traditional biomanufacturing approaches.

The company's technology represents what CEO Michael Heltzen describes as "the 4th industrial revolution at the intersection of biology and technology." eXoZymes' platform offers partners access to design and run enzyme pathways to produce target chemicals, providing a scalable, lower-impact alternative to petrochemical processes, natural extraction, and conventional synthetic biology methods. This approach is particularly timely as industries seek more sustainable manufacturing solutions.

David Shapiro, CEO of B2i Digital, emphasized the significance of eXoZymes' technology, stating that "with its cell-free enzyme technology that targets the scale-up bottleneck seen in first-generation synthetic biology, the company offers a timely story for investors focused on sustainable industrial biotechnology." The platform aims to replace selected petrochemical processes with what the company describes as "lower-impact biosolutions" that could transform multiple industries.

eXoZymes represents a historic first in biomanufacturing by freeing enzyme-driven chemical reactions from cellular limitations. The company's advanced enzymes, called exozymes, are enhanced through AI and bioengineering to thrive in bioreactors without the use of living cells. This innovation transforms biomass into essential natural products, medicines, chemicals, and biofuels, offering partners a commercially viable path to scalable and sustainable production of small molecules at industrial scale.

The company initially targets low volume, high value natural products with potential pharmaceutical applications, positioning itself at the forefront of the next generation of biomanufacturing. According to Heltzen, "We believe that the next generation of biomanufacturing is cell-free," and the collaboration with B2i Digital will enhance the company's visibility among investors who understand the value of their scalable enzyme-based approach.

This development matters because it addresses critical limitations in current biomanufacturing methods while offering a more sustainable alternative to petrochemical processes. The technology's potential impact extends across multiple sectors including pharmaceuticals, chemicals, and biofuels, potentially reducing environmental impact while improving production efficiency. For more information about B2i Digital's services, visit https://b2idigital.com, and to learn more about eXoZymes' technology platform, visit https://exozymes.com.